<SEC-DOCUMENT>0001193125-20-293186.txt : 20201228
<SEC-HEADER>0001193125-20-293186.hdr.sgml : 20201228
<ACCEPTANCE-DATETIME>20201113170828
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-20-293186
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Novus Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g50967dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:1.00em" ALIGN="right">


<IMG SRC="g50967dsp01a.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Ryan A.
Murr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Direct: +1
415.393.8373&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Fax: +1 415.374.8430&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">RMurr@gibsondunn.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;13, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Via EDGAR Submission </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and
Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office
of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jason Drory and Joe McCann </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novus Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Preliminary Proxy Statement on Schedule 14A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Filed October 23, 2020 (amended November 13, 2020) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">File No. 001-36620 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Drory and
Mr.&nbsp;McCann </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novus Therapeutics, Inc. (the &#147;Company&#148;) has filed today with the Securities and Exchange Commission (the
&#147;Commission&#148;) Amendment No.&nbsp;1 (&#147;Amendment No.&nbsp;1&#148;) to the Company&#146;s Preliminary Proxy Statement on Schedule 14A, initially filed with the Commission on October&nbsp;23, 2020 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-36620)</FONT> (the &#147;Preliminary Proxy Statement&#148;). This letter, together with Amendment No.&nbsp;1, sets forth the Company&#146;s responses to the comments contained in a letter from the staff
of the Commission (the &#147;Staff&#148;), dated November&nbsp;6, 2020 (the &#147;Comment Letter&#148;), relating to the Preliminary Proxy Statement. The responses set forth herein are based upon information provided to Gibson, Dunn&nbsp;&amp;
Crutcher LLP by the Company. The responses are keyed to the numbering of the comments in the Comment Letter and to the headings used in the Comment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms used but not otherwise defined in this letter have the respective meanings ascribed to such terms in Amendment No.&nbsp;1 to the Preliminary Proxy
Statement. Page references in the responses set forth below are to pages in the clean copy of Amendment No.&nbsp;1. The Company respectfully requests that the Staff confirm that it has no further comments to the Preliminary Proxy Statement so that
it may file a Definitive Proxy Statement on Schedule 14A on November&nbsp;20, 2020, or as soon as practicable thereafter. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the Company, we
advise you as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Reasons for the Transactions, page 13 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that Novus and its management team negotiated the &#147;most favorable equity
split&#148; for Novus stockholders. Please revise your disclosure to quantify the equity split by providing the actual percentage ownership existing Novus stockholders will own on a fully-diluted basis following the Anelixis Acquisition.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page 13 of
Amendment No.&nbsp;1 to the Preliminary Proxy Statement to add the requested information regarding the percentage ownership retained by legacy Novus stockholders. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that your board of directors considered the Anelixis Acquisition to be more
favorable to your stockholders than a potential liquidation. Please revise to quantify the liquidation value considered by the Board and discuss the basis for the calculation and any material assumptions.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page 13 of Amendment No.&nbsp;1 to the
Preliminary Proxy Statement to add the requested information regarding the estimated liquidation value at various points in time and the factors affecting such value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g50967dsp01c.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50967dsp01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 12, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Proposal No.&nbsp;1: Approval of Conversion Proposal, page 46 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I></I>3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I>We note that your Proposal No.1 Approval of Conversion Proposal is a result of your<I> acquisition of
Anelixis. Please revise your proxy statement to provide all of the information relating to Anelixis and the acquisition that is required by Item 14(b)(7) of Schedule 14A, including the information required by Items 1005(b) and 1011(a)(1) of
Regulation <FONT STYLE="white-space:nowrap">M-A.</FONT> Please refer to Note A of Schedule 14A. </I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>As
discussed with the Staff in a telephone conference call on November&nbsp;10, 2020, the Company has revised the disclosure on pages 13 and 47 of Amendment No.&nbsp;1 to the Preliminary Proxy Statement to provide enhanced disclosure regarding the
background of the Anelixis Acquisition and the interests of certain parties in the Acquisition. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your table under the subheading &#147;Shares Issuable Upon Conversion.&#148; Please revise this
section to indicate the total number of shares of common stock issued and reserved for issuance upon the approval of this conversion proposal. In addition, please disclose the aggregate shares of common stock issuable upon conversion in your
narrative &#147;Overview&#148; <FONT STYLE="white-space:nowrap">sub-section</FONT> directly above.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:
</B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page 47 of Amendment No.&nbsp;1 to the Preliminary Proxy Statement to include the requested total share information. We note that the Company intends to complete
this information in the definitive proxy statement once the size of the equity plan that is the subject of Proposal No. 2 has been approved by the Novus Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GIBSON, DUNN&nbsp;&amp; CRUTCHER LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ryan A. Murr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ryan A. Murr</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">David-Alexandre Gros, Chief Executive Officer, Novus Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">James J. Moloney, Gibson Dunn&nbsp;&amp; Crutcher LLP </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g50967dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50967dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M1?>1UP>.M$J4H)2>PH58S?*MR:_U2+3$5YUD*,P4%%SR3@"E"#GL5.:B,O\
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MNM-N#<0J(PR+E6 X'-:5*<)2YHRT,Z<YJ-G$T]*LY;2":6<?Z1<2&60+T!Z
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g50967dsp01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50967dsp01a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MMM<5%GFEC 1HVV'!9"02,]CE0<^U #I]"BEMK*-;B6*6R&(ID(##Y=IS[8H
MK)X2LHDQ#-.L@G2=9"^6#K&(P>>ORY_.@!8_"\$!0V]U-&T:1JC<$@HA0-^*
MDB@"6[\-6=[&Z3/*=THF+;N=XC$8/Y*#]: )].T>+3GDD61GDD148D 9 +$<
M#_?- %";PI%+'<0_;9UAEN1=A!CY)!*),C_@2_K0!H66D16ES+<NYGN90H:1
MP,_+G'\Z -&@!,B@ SB@ R* #(Q0 M " YZ4 +TH 3(H 6@ S0 4 % !0 4
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MCO/)"Z1EFV;-^6R%)Q\GIWH DUC7?[,TN+48H%N('P<AR.#TYVD >[8 [D4
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MR6OV97G5/,:3(F8'+$EN<YZD\4 1SZ!8W%J;:43& H8_+$S!=A !7&>F!TH
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A6[&=HQG'3^= %F@ H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g50967dsp01c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50967dsp01c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M51CS HX'0 ;!@>YS0 [2-%EM-<U/4YS\USL1%!X^489P/X=Q )'/W10!8O-
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MY;6D#8;=N (^<+C .3G]: *WBJ_O;&6"6"],-O%#)+-'$8_-(7'S[7X=0,Y
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J#^8 T8.'_O?7WH FCBCBW".-4W,6;:,9)ZD^] #Z "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
